A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome

Myelodysplastic syndrome (MDS) treatment remains a big challenge due to the heterogeneous nature of the disease and its ability to progress to acute myeloid leukemia (AML). The only curative option is allogeneic hematopoietic stem cell transplantation (HSCT), but most patients are unfit for this pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Arellano-Ballestero, Helena, Sabry, May, Lowdell, Mark W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954109/
https://www.ncbi.nlm.nih.gov/pubmed/36831300
http://dx.doi.org/10.3390/cells12040633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954109/
https://www.ncbi.nlm.nih.gov/pubmed/36831300
http://dx.doi.org/10.3390/cells12040633

Ejemplares similares